Gene Therapies Come to Saudi Arabia for 500,000 Patients

Over half a million people in Saudi Arabia live with sickle cell disease or beta-thalassemia, rare genetic blood disorders that require lifelong treatment. Now, a new partnership promises to bring transformative one-time gene therapies directly to them.

Genetix Biotherapeutics and Saudi pharmaceutical leader SPIMACO announced an agreement to manufacture and distribute two groundbreaking treatments, LYFGENIA and ZYNTEGLO, across Saudi Arabia and the broader Middle East region. These therapies work by adding healthy genes to patients' own blood stem cells, potentially eliminating the need for ongoing treatments.

For families dealing with these conditions, the news represents hope for a radically different future. Sickle cell disease causes painful episodes when blood cells become misshapen and block circulation, while beta-thalassemia requires regular blood transfusions to survive.

The partnership goes beyond simply importing treatments. SPIMACO will establish cutting-edge manufacturing facilities right in Saudi Arabia, making the therapies more accessible and affordable for regional patients.

"This represents an important milestone in expanding global access to our transformative one-time treatments," said David Meek, CEO of Genetix Biotherapeutics. The collaboration combines Genetix's pioneering gene therapy expertise with SPIMACO's established infrastructure and manufacturing capabilities.

Professor Ahmed Hamdan Aljedai, SPIMACO's Vice Chairman and Managing Director, emphasized the alignment with Saudi Arabia's national healthcare priorities. The partnership supports the Kingdom's vision of building advanced medical capabilities while addressing urgent patient needs.

The Ripple Effect

This collaboration signals a broader shift in how cutting-edge medical treatments reach patients worldwide. By establishing local manufacturing, the partnership creates a sustainable model that could inspire similar efforts in other regions where rare diseases carry heavy burdens.

The move also represents significant progress for Middle Eastern healthcare infrastructure. Building state-of-the-art gene therapy manufacturing capabilities in Saudi Arabia develops local expertise and creates a foundation for future medical innovations in the region.

For the 500,000 people living with these conditions across the Middle East, the partnership transforms abstract scientific progress into tangible hope. Families who once faced limited options now have a path to potentially curative treatments without traveling halfway around the world.

As gene therapies become more accessible globally, this partnership shows how international collaboration can turn medical breakthroughs into real-world solutions for patients who need them most.